Log In
Print
BCIQ
Print
Print this Print this
 

DAC HYP, Daclizumab high-yield process (Zinbryta)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionHumanized mAb against IL-2 receptor alpha chain (CD25)
Molecular Target Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of ActionBinds interleukin-2 (IL-2) receptor alpha chain (CD25); Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentRegistration
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat relapsing forms of multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation

Partner

Biogen Inc.; UCB Group; UCB Group


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$1,171.9M

$1,171.9M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today